Susan Shiff

Susan Shiff currently serves as the Chief Executive Officer and Board Member of Huma.AI since July 2024. In addition to this role, Susan holds positions as a Board Director at Tvardi Therapeutics and Synthace Limited, as well as a member of the External Review Committee for the Office of Technology Development at Memorial Sloan Kettering Cancer Center. Previous experience includes serving as a Board Member for Cara Therapeutics, where involvement included the Compensation Committee and Nominating and Corporate Governance Committee. Susan holds a PhD in Research Methods/Epidemiology from UCLA and an MBA in Management from Cornell University.